Superworth

Aptevo Therapeutics free cash flow APVO

Cash from operations less capital spending, by quarter and over the last twelve months, from 2015.

Last 12 months, to Dec 31, 2022
n/m
a quarter missing
Latest quarter, Q4 FY22
−$5.9M
Fiscal year 2022
n/a

Aptevo Therapeutics' twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q4 FY22, it was −$5.9M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2022n/an/a
FY2021−$22.4Mn/a
FY2019−$42.5Mn/a
FY2018−$52.4Mn/a
FY2017−$43Mn/a
FY2016−$39.4Mn/a
FY2015n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q4 FY22−$5.9Mn/an/a
Q3 FY22−$6.9Mn/an/a
Q4 FY21−$4Mn/a−$22.4M
Q3 FY21−$5.3Mn/an/a
Q2 FY21−$5.4Mn/an/a
Q1 FY21−$7.7Mn/an/a
Q4 FY19−$5.1Mn/a−$42.5M
Q3 FY19−$7.5Mn/a−$44.8M
Q2 FY19−$15.9Mn/a−$48.7M
Q1 FY19−$14Mn/a−$48.9M
Q4 FY18−$7.3Mn/a−$52.4M
Q3 FY18−$11.5Mn/a−$60.8M

Against its peers

Companies in Healthcare nearest Aptevo Therapeutics' size, closest first, today.

CompanyFree cash flow yield
APVOAptevo Therapeuticsn/m
OXBROXBRIDGE RE HOLDINGSn/m
EDUCEducational Development2.0%
GTIMGood Times Restaurants19.3%
MDRRMedalist Diversifiedn/m
BCGBinah Capital30.9%
VIPVulcan Infrastructure & Powern/m
MXCMexco Energy7.3%
CKXCKX Landsn/m
MSGMMotorsport Gamesn/m
ATCHAtlasClearn/m
Peer median13.3%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Aptevo Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.